A novel anti-OX40 human monoclonal antibody that blocks OX40/OX40L signaling and depletes OX40⁺ T cells

Abstract

Tumor necrosis factor receptor superfamily member 4 (TNFRSF4), also known as OX40, plays a crucial role in the regulation of T-cell immune responses under normal physiological conditions. Abnormal expression of OX40 and its cognate ligand OX40L (TNFSF4) have been associated with various autoimmune diseases, indicating that blocking the OX40/OX40L pathway could be a promising strategy for the treatment of a broad range of T cell-mediated autoimmune diseases. Here, we screened and characterized a fully human anti-OX40 antibody (JY007) from a naïve human scFv phage library. JY007 has an affinity constant of 7.71 nmol/L and effectively inhibited the OX40-OX40L interaction at both molecular and cellular levels, with IC₅₀ values of 1.088 and 10.12 nmol/L, respectively. Furthermore, JY007 demonstrated the ability to deplete activated T lymphocytes through antibody-dependent cellular cytotoxicity (ADCC) activity, with an EC₅₀ of 5.592 pmol/L. The combination of ADCC and its antagonist activity against OX40 suggests potential efficacy in suppressing inflammatory responses mediated by the OX40/OX40L pathway. Additionally, we employed molecular docking, site-directed mutagenesis, and competitive ELISA to pinpoint the epitopes on OX40. The results revealed that JY007 binds to Pro³⁷, Ser³⁸, and Asp⁴⁰ of OX40. Interestingly, we also found that the most potent anti-OX40 antibody drug in the clinical stage, KHK4083, binds to different OX40 amino-acid residues, including Asp⁷⁴, Lys⁸², Asp¹¹⁷, Ser¹¹⁸, Tyr¹¹⁹, and Lys¹²⁰. This divergence suggests that the novel monoclonal antibody JY007 holds promise as a potential therapeutic option for patients with atopic dermatitis and may find broad applications in the treatment of autoimmune diseases.

Keywords

Atopic dermatitis / OX40 / Phage display / Fully human antibody / Computer simulation / Epitope scanning / Medical and Health Sciences / Immunology / Biological Sciences / Biochemistry and Cell Biology

References

[1] AmbrosettiF, Jimenez-GarciaB, Roel-TourisJ, BonvinA. Modeling antibody-antigen complexes by information-driven docking. Structure, 2020, 28: 119-129.

[2] ArchRH, ThompsonCB. 4–1BB and OX40 are members of a tumor necrosis factor (TNF)-nerve growth factor receptor subfamily that bind TNF receptor-associated factors and activate nuclear factor kappaB. Mol C, 1998, 18: 558-565

[3] BadloeFMS, De VrieseS, CoolensK, Schmidt-WeberCB, RingJ, GutermuthJ, Kortekaas KrohnI. IgE autoantibodies and autoreactive T cells and their role in children and adults with atopic dermatitis. Clin Transl Allergy, 2020, 10: 34.

[4] BonamonteD, FiloniA, VestitaM, RomitaP, FotiC, AngeliniG. The role of the environmental risk factors in the pathogenesis and clinical outcome of atopic dermatitis. Biomed Res Int, 2019, 2019: 2450605.

[5] BrandTM, IidaM, WheelerDL. Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther, 2011, 11: 777-792.

[6] CalderheadDM, BuhlmannJE, van den EertweghAJ, ClaassenE, NoelleRJ, FellHP. Cloning of mouse OX40: a T cell activation marker that may mediate T-B cell interactions. J Immunol, 1993, 151: 5261-5271.

[7] CavanaghMM, HussellT. Is it wise to target the late costimulatory molecule OX40 as a therapeutic target?. Arch Immunol Ther Exp (Warsz), 2008, 56: 291-297.

[8] ChenJ, XuL, ZhangX-Q, LiuX, ZhangZ-X, ZhuQ-M, LiuJ-Y, IqbalMO, DingN, ShaoC-L, WeiM-Y, GuY-C. Discovery of a natural small-molecule AMP-activated kinase activator that alleviates nonalcoholic steatohepatitis. Mar Life Sci Technol, 2023, 5: 196-210.

[9] CompaanDM, HymowitzSG. The crystal structure of the costimulatory OX40-OX40L complex. Structure, 2006, 14: 1321-1330.

[10] CunninghamBC, JhuraniP, NgP, WellsJA. Receptor and antibody epitopes in human growth hormone identified by homolog-scanning mutagenesis. Science, 1989, 243: 1330-1336.

[11] FarcetJP, OudhririN, GourdinMF, BouguetJ, FradeliziD, ReyesF. Heterogeneous accessory cell requirement for human peripheral blood T lymphocyte activation by PHA into IL-2-responsive colony-forming cells. Cell Immunol, 1984, 87: 167-176.

[12] FurueM, FurueM. OX40L-OX40 signaling in atopic dermatitis. J Clin Med, 2021, 10: 2578.

[13] Guttman-YasskyE, PavelAB, ZhouL, EstradaYD, ZhangN, XuH, PengX, WenHC, GovasP, GudiG, CaV, FangH, SalhiY, BackJ, ReddyV, BissonnetteR, MaariC, GrossmanF, WolffG. GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis. J Allergy Clin Immunol, 2019, 144: 482-493.

[14] Guttman-YasskyE, SimpsonEL, ReichK, KabashimaK, IgawaK, SuzukiT, ManoH, MatsuiT, EsfandiariE, FurueM. An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. Lancet, 2023, 401: 204-214.

[15] KaderHA, AzeemM, JwayedSA, Al-ShehhiA, TabassumA, AyoubMA, HettaHF, WaheedY, IratniR, Al-DhaheriA, MuhammadK. Current insights into immunology and novel therapeutics of atopic dermatitis. Cells, 2021, 10: 1392.

[16] LaughterMR, MaymoneMBC, MashayekhiS, ArentsBWM, KarimkhaniC, LanganSM, DellavalleRP, FlohrC. The global burden of atopic dermatitis: lessons from the global burden of disease study 1990–2017. Br J Dermatol, 2021, 184: 304-309.

[17] LeAM, TorresT. OX40-OX40L inhibition for the treatment of atopic dermatitis-focus on Rocatinlimab and Amlitelimab. Pharmaceutics, 2022, 14: 2753.

[18] LiM, YangQ, ZhangY. Effects of CD134 monoclonal antibody on hemolysis activities and expression of perforin in peripheral blood mononuclear cells of systemic lupus erythematosus patients. Hybridoma (Larchmt), 2007, 26: 191-200.

[19] LiuJ-Y, JiangY-Y, LiP-J, YaoB, SongY-J, GaoJ-X, SaidG, GaoY, LaiJ-Y, ShaoC-L. Discovery of a potential bladder cancer inhibitor CHNQD-01281 by regulating EGFR and promoting infiltration of cytotoxic T cells. Mar Life Sci Technol, 2024, 6: 502-514.

[20] LiuX, WangY, SunL, XiaoG, HouN, ChenJ, WangW, XuX, GuY. Screening and optimization of shark nanobodies against SARS-CoV-2 spike RBD. Antiviral Res, 2024, 226. 105898

[21] MalmstromV, ShiptonD, SinghB, Al-ShamkhaniA, PuklavecMJ, BarclayAN, PowrieF. CD134L expression on dendritic cells in the mesenteric lymph nodes drives colitis in T cell-restored SCID mice. J Immunol, 2001, 166: 6972-6981.

[22] Martinez-NavioJM, FuchsSP, MendesDE, RakaszEG, GaoG, LifsonJD, DesrosiersRC. Long-term delivery of an anti-SIV monoclonal antibody with AAV. Front Immunol, 2020, 11: 449.

[23] MirditaM, SchutzeK, MoriwakiY, HeoL, OvchinnikovS, SteineggerM. ColabFold: making protein folding accessible to all. Nat Methods, 2022, 19: 679-682.

[24] MocciaAA, TavernaC, ScharS, VanazziA, RondeauS, HitzF, MingroneW, PabstT, CevreskaL, Del GiglioA, RaatsJ, RauchD, VorobiofDA, LohriA, RuegseggerC, Biaggi RudolfC, RusterholzC, HayozS, GhielminiM, ZuccaE. Prolonged rituximab maintenance in follicular lymphoma patients: long-term results of the SAKK 35/03 randomized trial. Blood Adv, 2020, 4: 5951-5957.

[25] NairAK, BaierLJ. Using luciferase reporter assays to identify functional variants at disease-associated Loci. Methods Mol Biol, 2018, 1706: 303-319.

[26] NakagawaH, IizukaH, NemotoO, ShimabeM, FurukawaY, KikutaN, OotakiK. Safety, tolerability and efficacy of repeated intravenous infusions of KHK4083, a fully human anti-OX40 monoclonal antibody, in Japanese patients with moderate to severe atopic dermatitis. J Dermatol Sci, 2020, 99: 82-89.

[27] NewsomM, BashyamAM, BaloghEA, FeldmanSR, StrowdLC. New and emerging systemic treatments for atopic dermatitis. Drugs, 2020, 80: 1041-1052.

[28] NoharaC, AkibaH, NakajimaA, InoueA, KohCS, OhshimaH, YagitaH, MizunoY, OkumuraK. Amelioration of experimental autoimmune encephalomyelitis with anti-OX40 ligand monoclonal antibody: a critical role for OX40 ligand in migration, but not development, of pathogenic T cells. J Immunol, 2001, 166: 2108-2115.

[29] OhshimaY, TanakaY, TozawaH, TakahashiY, MaliszewskiC, DelespesseG. Expression and function of OX40 ligand on human dendritic cells. J Immunol, 1997, 159: 3838-3848.

[30] RubyCE, RedmondWL, HaleyD, WeinbergAD. Anti-OX40 stimulation in vivo enhances CD8⁺ memory T cell survival and significantly increases recall responses. Eur J Immunol, 2007, 37: 157-166.

[31] SadunRE, HsuWE, ZhangN, NienYC, BergfeldSA, SabzevariH, LutsiakME, KhawliL, HuP, EpsteinAL. Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. J Immunother, 2008, 31: 235-245.

[32] SmithMR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene, 2003, 22: 7359-7368.

[33] SoT, IshiiN. The TNF-TNFR family of co-signal molecules. Adv Exp Med Biol, 2019, 1189: 53-84.

[34] SongJ, SoT, CroftM. Activation of NF-kappaB1 by OX40 contributes to antigen-driven T cell expansion and survival. J Immunol, 2008, 180: 7240-7248.

[35] SternerA, ZehetmeierC. High-throughput IgG conversion of phage displayed Fab antibody fragments by AmplYFast. Methods Mol Biol, 2017, 1575: 121-143.

[36] VanameeES, FaustmanDL. Structural principles of tumor necrosis factor superfamily signaling. Sci Signal, 2018, 11: eaao4910.

[37] WebbGJ, HirschfieldGM, LanePJ. OX40, OX40L and autoimmunity: a comprehensive review. Clin Rev Allergy Immunol, 2016, 50: 312-332.

[38] WeinbergAD, RiveraMM, PrellR, MorrisA, RamstadT, VettoJT, UrbaWJ, AlvordG, BunceC, ShieldsJ. Engagement of the OX-40 receptor in vivo enhances antitumor immunity. J Immunol, 2000, 164: 2160-2169.

[39] XiX, XiaoG, AnG, LiuL, LiuX, HaoP, WangJY, SongD, YuW, GuY. A novel shark single-domain antibody targeting OGT as a tool for detection and intracellular localization. Front Immunol, 2023, 14: 1062656.

[40] YanJ, SuH, XuL, WangC. OX40-OX40L interaction promotes proliferation and activation of lymphocytes via NFATc1 in ApoE-deficient mice. PLoS ONE, 2013, 8. e60854

[41] YangB, LinSJ, RenJY, LiuT, WangYM, LiCM, XuWW, HeYW, ZhengWH, ZhaoJ, YuanXH, LiaoHX. Molecular docking and molecular dynamics (MD) simulation of human anti-complement factor H (CFH) antibody Ab42 and CFH polypeptide. Int J Mol Sci, 2019, 20: 2568.

RIGHTS & PERMISSIONS

The Author(s)